Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.
A merger and a $150 million capital infusion is giving Werewolf's next chapter more firepower, but investors still face risks.
Werewolf Therapeutics stock explodes higher on a merger agreement with Ambros Therapeutics. But is there any further upside left in HOWL shares?
Werewolf Therapeutics Inc (NASDAQ:HOWL) shares soared 120% in premarket trading on Friday after the biotechnology company agreed to merge with Ambros Therapeutics Inc alongside a $150 million private placement. The all-stock combination will create a company centred on the development of neridronate, Ambros Therapeutics’ late-stage drug candidate for Complex Regional Pain Syndrome Type 1 (CRPS-1).
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an...
This is the newest page. Registered accounts read further back.